Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact

Clinical Pathways

Home
Who We Are
Who We Are
Testimonials
Collaborations
Consulting
Inspection Readiness
GxP Auditing
Quality Systems
Quality Risk Management
Monitoring Services
Training
GCP Training Services
Training Courses
DIGR-ACT
DIGR-ACT - Home
DIGR-ACT - About
DIGR-ACT - Contact Us
Online Store
Catalog
Blog
Contact
June 8, 2026
Guest User
Update - ISO 14155 Device GCP 2026 and Clinical ...

06/07/2026

-

In March 2026, the International Organization for Standardization (ISO) published the fourth edition of ISO 14155:2026, replacing the previous edition from 2020. This is the medical device global reference for GCP conduct that many regulatory authorities recognize. Clinical Pathways offers an ISO 14155 Comparison Tool to support you to do an impact analysis and plan updates to SOPs, templates and tools for your trials.

Update - ISO 14155 Device GCP 2026 and Clinical Pathway’s New eLearning & Comparison Tool
May 26, 2026
Guest User
Get Ready for AI Assisted FDA Inspections Part ...

05/26/2026

-

The US Food and Drug Administration’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) collaborated with the European Medicines Agency (EMA) to develop 10 Guiding Principles of Good AI Practice in Drug Development. They are intended to be a foundational basis for developing good practices with AI, addressing the unique nature of AI, as well as cultivating its future growth.

Get Ready for AI Assisted FDA Inspections Part 3/3
April 30, 2026
Guest User
Get Ready for AI Assisted FDA Inspections Part ...

04/30/2026

-

In addition to the launch of Elsa, in a press announcement on December 1, 2025, the FDA broadcasted the deployment of Agentic AI capabilities for their employees. Agentic AI is unique from LLM AI due to its capability to plan, reason, and execute multi-step actions in order to achieve a specific goal. This means it can be used to assist with more complex tasks.

Get Ready for AI Assisted FDA Inspections Part 2/3
April 7, 2026
Guest User
Get Ready for AI Assisted FDA Inspections Part ...

04/07/2026

-

On June 2, 2025, the U.S. Food and Drug Administration (FDA) announced the launch of their Artificial Intelligence (AI) Tool: Elsa. AI has been seen in many parts of the clinical research ecosystem in recent years such as trial and protocol design, participant recruitment, and safety monitoring, all of which have the potential to enhance trial efficiency and safety.

Get Ready for AI Assisted FDA Inspections Part 1/3
March 23, 2026
Guest User
FDA releases Final Guidance for BIMO Inspection ...

03/23/2026

-

On December 19th, 2025, the US Food and Drug Administration released the finalized guidance for industry: Processes and Practices Applicable to Bioresearch Monitoring Inspections. The guidance details the processes and practices of Bioresearch Monitoring Program (BIMO) inspections of FDA-regulated establishments NOT specified in existing FDA guides or manuals.

FDA releases Final Guidance for BIMO Inspection Program Processes and Practices Not Found in Current Industry Guides or Manuals
Sandra Sather
July 18, 2014

Finding Balance

Sandra Sather
July 18, 2014

07/18/2014

Check out the Key Note Corner for iiBig!

Sandra Sather
July 18, 2014

NEW FDA Draft Guidance on Informed Consent JULY 2014

Sandra Sather
July 18, 2014

07/18/2014

Tomorrow, July 24th, join us for an Informed Consent (IC) discussion that includes the new FDA IC Information Sheet, released last week. Please join us at 1pm EST.

Sandra Sather
July 2, 2014

Informed Consent

Sandra Sather
July 2, 2014

07/02/2014

Changes to the Declaration of Helsinki /DoH...the interpretations of the 2013 changes related to IC are being debated related to who can obtain consent; can this be delegated vs. required to include or IC signed off by the PI?

Sandra Sather
June 26, 2014

Root Cause Analysis Opportunities for GCP

Sandra Sather
June 26, 2014

06/26/2014

Root cause analysis (RCA) is an important process that is not inherent and involves scientific principles. Tools used to perform RCA (e.g. 5 Whys, fishbone diagrams, cause mapping, force field analysis, etc.) do not teach an individual how to perform RCA.

Sandra Sather
June 9, 2014

RBM: Round Table Discussion

Sandra Sather
June 9, 2014

06/09/2014

There are many opportunities where root cause analysis (RCA) can be used in running clinical trials, but not just for non-compliance root cause assessment. Another important opportunity to use root cause analysis is in an anticipatory environment.

Newer Posts
Older Posts
 
Archive List
  • 2013 6
  • 2014 31
  • 2015 25
  • 2016 21
  • 2017 31
  • 2018 55
  • 2019 56
  • 2020 63
  • 2021 50
  • 2022 39
  • 2023 27
  • 2024 25
  • 2025 31
  • 2026 7

No results found

Subscribe to Blogs and Newsletters.

By signing up, you agree to our our Privacy Policy. You may unsubscribe from emails at any time.

Thank you! You will receive a confirmation email shortly.

Back to Top
Clinical Pathwaysinfo@clinicalpathwaysresearch.com

Cookie Notice | License Agreement | Privacy Policy | Return Policy | Terms and Conditions | Data Security Policy | Confidentiality Policy

© 2026 Clinical Pathways. All rights reserved.